Daniel Streblow, Ph.D.
The focus of the Streblow laboratory is on defining the role of human cytomegalovirus (HCMV) in the development of vascular disease and chronic rejection of organ allografts. The role of CMV in these diseases is still uncharacterized. Dr. Streblow's lab studies the following topics: 1) Determining the mechanisms of HCMV-accelerated vascular disease through identification of the viral genes expressed during these diseases using a HCMV microarray chip developed by Dr. Streblow's laboratory in combination with the Shared Microarray Core at VGTI. Once identified, the function of these viral genes will be examined using in vitro and in vivo models of CMV-accelerated vascular disease. 2) Determining the mechanisms of CMV-accelerated vascular disease in both mouse models of atherosclerosis and rat organ transplantation models using a DNA microarray approach. The Streblow lab in conjunction with Dr. Susan Orloff’s laboratory at OHSU has determined RCMV in vivo gene expression in infected rats and has begun functional studies of these genes. 3) Determine viral and host gene expression during the development of atherosclerosis and transplant vascular sclerosis, the vascular lesion associated with chronic allograft rejection 4) determining the mechanisms of viral acceleration of chronic allograft rejection from latently infected donor, which is the most common cause of HCMV-associated disease in transplant patients associated with expression during the different stages of viremia associated with CMV including 5) Determining the function of CMV-encoded chemokine receptors in the context of viral pathogenesis and acceleration of vascular disease. Dr. Streblow was recently awarded an ONPRC pilot project grant to study Chikungunya in a NHP model.
Dr. Daniel Streblow received his B.S. in Pharmacology/Toxicology from the University of Wisconsin-Madison in 1992. He graduated from University of Wisconsin-Madison with a Ph.D. in Viral Pathogenesis in 1997. Dr. Streblow received a NIH post-doctoral fellowship and worked with Dr. Jay A. Nelson in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University. He is currently an Associate Scientist at the Vaccine and Gene Therapy Institute and Research Assistant Professor at the Department of Molecular Microbiology and Immunology.
Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol. 2014 Aug;88(15):8213-26. (doi: 10.1128/JVI.01032-14.) [PMID: 24829346, PMCID: PMC4135940] Epub 2014 May 14.
Malouli D, Hansen SG, Nakayasu ES, Marshall EE, Hughes CM, Ventura AB, Gilbride RM, Lewis MS, Xu G, Kreklywich C, Whizin N, Fischer M, Legasse AW, Viswanathan K, Siess D, Camp DG 2nd, Axthelm MK, Kahl C, DeFilippis VR, Smith RD, Streblow DN, Picker LJ, Früh K. Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. J Clin Invest. 2014 May 1;124(5):1928-44. [PMID: 24691437, PMCID: PMC4002596] Epub 2014 Apr 1.
Hakki M, Goldman DC, Streblow DN, Hamlin KL, Krekylwich CN, Fleming WH, Nelson JA. HCMV infection of humanized mice after transplantation of G-CSF-mobilized peripheral blood stem cells from HCMV-seropositive donors. Biol Blood Marrow Transplant. 2014 Jan;20(1):132-5. (doi: 10.1016/j.bbmt.2013.10.019.) [PMID: 24161922, PMCID: PMC3922710] Epub 2013 Oct 23.